Home | Clinical Care | Research | Training | Division Activities

Education and Training:

M.D., Crimea Medical Institute, Simferopol, Ukraine (1987-93)

Critical Care Medicine Residency, Department of Critical Care and Anesthesiology, Crimea Medical Institute Medical Center, Simferopol, Ukraine (1993-95)

Post-doctoral Research Fellow, Division of Rheumatology and Clinical Immunology, University of Maryland, Baltimore, MD (1995-00)

Internship, York Hospital, York, PA (2000-01)

Hematology/Oncology Fellow, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA (2003-06)

Andrei Shustov, M.D.
Associate Professor of Medicine, Division of Hematology
University of Washington School of Medicine

Research Associate
Fred Hutchinson Cancer Research Center
Office Address:
Seattle Cancer Care Alliance
Mailbox G3-200
825 Eastlake Ave., East
Seattle, WA 98109-1024

Phone:  (206) 288-6739
Fax:      (206) 288-6473
E-mail:  ashustov@u.washington.edu


Development of novel therapeutic strategies and implementation of targeted biologic agents into treatment paradigms of peripheral T-cell lymphomas and cutaneous T-cell lymphomas


Non-Hodgkin and Hodgkin lymphomas; acute lymphoblastic leukemia


Active Clinical trials:

UW-6640 Phase II Prospective Study of Pralatrexate and Gemcitabine for patients with relapsed PTCL.

UW-08020 Phase II Prospective Study of Romidepsin (Depsipeptide) for patients with relapsed PTCL.

UW-6914 Phase II Study of Vorinostat (SAHA) for patients with untreated CTCL.

UW-08032 Phase II Study of SGN-35 (anti-CD30 mAb with immunotoxin) for patients with relapsed ALCL, ALK-negative.

UW-08004 Phase II Study of Forodesine (BCX1777) in patients with relapsed CTCL.

UW-6774 Phase II Study of Pralatrexate in patients with relapsed CTCL.

UW-6959 Phase II Study of Pegylated Asparaginase with intensive chemotherapy for patients with newly diagnosed acute lymphoblastic leukemia.


Via CS, Nguyen P, Shustov AR, Drappa J, Elkon KB.  A major role of the Fas pathway in Acute Graft-versus-Host Disease.  J. Immunol. 157:5387-5393, 1996.

Shustov AR, Nguyen P, Finkelman FD, Elkon KB and Via CS.  Differential expression of Fas and Fas ligands in acute and chronic GVHD: upregulation of Fas and Fas ligand requires CD8+T cell activation and INF-gamma production.  J. Immunol. 161:2848-2855, 1998.

Shustov AR, Luzina IG, Nguyen P, Papadimitriou JC,Handwerger BS, Elkon KB and Via CS.  Role of perforin in controlling B cell hyperactivity and humoral autoimmunity.  J. Clin. Invest. 106(6):R39-R47, 2000.

Via CS, Shustov AR, Rus V, Lang T, Nguyen P, Finkelman FD.  In vivo neutralization of tumor necrosis factor alpha promotes humoral autoimmunity by preventing the induction cytotoxic T lymphocytes.  J. Immunol.  167:6821-6826, 2001.

Shustov AR and Savage KJ.  Does high-dose therapy and autologous hematopoietic stem cell transplantation have a role in the primary treatment of peripheral T-cell lymphomas?  ASH Evidence-based Review 2008, American Society of Hematology, Education Program Book.  Pages 39-41.

Shustov AR.  T-cell lymphoma-one name with a dozen faces. Leuke. Lymphoma 49(11):2033-2034,2008.

Puliaeva I, Puliaev R, Shustov AR, Hass M, and Via Cs.  Fas expression on antigen-specific T-cell responses but not for T-cell-dependent B cell responses.  J. Immunol. 181(9):5912-29, 2008.

Furman RR, Forero-Torres A, Shustov A, Drachman JG.  A phase I study of Dacetuzumab (SGN-40), a humanized anti-CD-40 monoclonal antibody) in patients with chronic lymphocytic leukemia.  Clin. Cancer Res. (in review).

Shustov AR, Rus V, Nguyen P and Via CS.  Murine Graft-versus-Host Disease: relevance to human lupus immunopathogenesis and therapy.  In: Lupus: Cellular and Molecular Pathogenesis.  G.T. Tsokos & G.M.Kammer (Eds),  pp 140-151, 2000.

Shustov AR and Via CS.  Transplantation and autoimmunity.  In: Molecular Pathology of Autoimmunity.  A.N. Theophilopoulos et al. (Eds), pp 1055-1065, 2001.

Shustov AR and Appelbaum FR.  T-cell acute lymphoblastic leukemia.  In: Adult Acute Lymphocytic Leukemia: Biology and Treatment. Humana Press (to be published in 2010).